Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2024 17:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for...
March 26, 2024 17:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...
February 01, 2024 11:00 ET | Source: GT Biopharma, Inc.

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
December 06, 2023 09:30 ET | Source: GT Biopharma, Inc.

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma,...
December 04, 2023 09:30 ET | Source: GT Biopharma, Inc.

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
November 06, 2023 09:30 ET | Source: GT Biopharma, Inc.

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
November 01, 2023 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Third Quarter 2023 Financial Results

IND submission for GTB-3650, 2nd generation nanobody TriKE® for treatment of CD33+ leukemia, expected in Q4 2023Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia...
August 07, 2023 09:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports Second Quarter 2023 Financial Results

Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and initiate clinical...
August 03, 2023 13:25 ET | Source: GT Biopharma, Inc.

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
May 15, 2023 17:00 ET | Source: GT Biopharma, Inc.

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and...